Trial Profile
A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational
- Acronyms ARC008
- Sponsors Aimmune Therapeutics
- 13 Dec 2023 Status changed from recruiting to completed.
- 12 Oct 2023 This trial has been completed in Italy , according to the European Clinical Trials Database record.
- 05 Oct 2023 This trial has been completed in Sweden (Date of the global end of the trial: 18-Apr-2023), according to the European Clinical Trials Database record.